Retina Pharmaceuticals company information, Employees & Contact Information

Ocular Therapeutix sharpens focus with retina-centric rebrand Fierce Pharma

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EyePoint Pharmaceuticals

AviadoBio snags option to UgeneX's retinal disease gene therapy FirstWord Pharma

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration EyePoint Pharmaceuticals

FDA green lights first drug for rare progressive retinal vascular disease FirstWord Pharma

Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant Encelto Fierce Pharma

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors EyePoint Pharmaceuticals

Roche's Chugai reports first Phase III Vabysmo data for rare retinal condition FirstWord Pharma

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration EyePoint Pharmaceuticals

Opus Genetics celebrates early win for retinal gene therapy in teen patient FirstWord Pharma

EyePoint Provides Company Update and Anticipated Development Milestones for 2025 EyePoint Pharmaceuticals

J&J's $130M gene therapy bet flunks rare retinal disease trial FirstWord Pharma

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints EyePoint Pharmaceuticals

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference EyePoint Pharmaceuticals

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

Roche's Vabysmo shows potential to treat eye disorder common in Asia Fierce Pharma

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema EyePoint Pharmaceuticals

Regeneron wins another FDA nod for powerhouse Eylea despite trial flops Fierce Pharma

After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME Fierce Pharma

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual Meeting EyePoint Pharmaceuticals

Regeneron's Eylea franchise suffers double whammy with sales decline and surprise FDA rejection Fierce Pharma

Roche's Vabysmo shows an edge over Regeneron's Eylea in retina drying Fierce Pharma

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy EyePoint Pharmaceuticals

Cirrus nabs $11M on quest for a gene therapy solution to AMD FirstWord Pharma

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EyePoint Pharmaceuticals

Apellis flags needle problems in hunt for Syfovre side effect source Fierce Pharma

Experts flag eye inflammation reports tied to Apellis' geographic atrophy med Syfovre Fierce Pharma

Apellis attempts to clear the air around Syfovre safety as eye drug launch gains steam Fierce Pharma

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting EyePoint Pharmaceuticals

Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles Fierce Pharma

Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2 GlobeNewswire

Novartis' hot new eye drug Beovu tied to potential vision loss: experts Fierce Pharma

Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, October 18-21 in Orlando GlobeNewswire

Regeneron's bid for high-dose Eylea scores early win, but the 'all important' data are still to come: analysts Fierce Pharma

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer EyePoint Pharmaceuticals

Apellis' eye drug Syfovre shows signs of uptick in demand FirstWord Pharma

Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration Fierce Pharma

Roche to reintroduce eye implant med Susvimo 2 years after recall Fierce Pharma

Apellis wins FDA approval for first geographic atrophy drug Fierce Pharma

Regeneron's high-dose Eylea shows staying power as company awaits FDA decision Fierce Pharma

Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey Fierce Pharma

Astellas wins FDA approval of eye disease drug Izervay and may have edge in market battle with Apellis Fierce Pharma

Apellis taps Henry Winkler to raise awareness of eye disease as drug launch ramps up Fierce Pharma

Analysts see uptake of Novartis' AMD therapy Beovu hit by safety concerns FirstWord Pharma

Genentech debuts animated short film spotlighting docs' trust in Vabysmo for their own loved ones Fierce Pharma

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema EyePoint Pharmaceuticals

Apellis takes it slow with first Syfovre DTC campaign Fierce Pharma

Despite COVID-19 and safety woes, Novartis still eyes blockbuster sales for Beovu Fierce Pharma

Top 10 drug launch disasters Fierce Pharma

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD EyePoint Pharmaceuticals

Novartis stands behind Beovu's safety, benefits after vision-loss warning Fierce Pharma

Apellis parries Astellas' long-term Izervay data with 3-year results on its rival GA med Syfovre Fierce Pharma

Aiming to push Beovu into diabetic macular edema, Novartis hopes longer dosing interval can fix eye drug's safety woes Fierce Pharma

Roche's Vabysmo holds up against Eylea in retinal vein occlusion studies FirstWord Pharma

EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting EyePoint Pharmaceuticals

'Lightning struck': How a safety alert shifted doctor sentiment on Novartis' Beovu Fierce Pharma

Novartis, stressing Beovu safety, matches Eylea in head-to-head diabetic macular edema trial Fierce Pharma

Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio Fierce Biotech

See that? Regeneron simulates retinal disease with virtual and augmented reality app Fierce Pharma

Novartis calls off 3 Beovu trials testing more frequent dosing on concerns of vision-threatening side effect Fierce Pharma

The top 10 most-expensive meds in the U.S.—and they're not the usual suspects Fierce Pharma